Pasireotide Evidence Guide
Pasireotide (Signifor) is FDA-approved for Cushing's disease in patients who fail surgery or are not surgical candidates, with Phase 3 data demonstrating meaningful UFC normalization. Its multi-receptor somatostatin analog profile (SST1/2/3/5) differentiates it from octreotide and allows ACTH suppression that octreotide cannot achieve. A validated, targeted treatment for a rare pituitary disorder.
Our Take
Pasireotide (Signifor) is FDA-approved for Cushing's disease in patients who fail surgery or are not surgical candidates, with Phase 3 data demonstrating meaningful UFC normalization. Its multi-receptor somatostatin analog profile (SST1/2/3/5) differentiates it from octreotide and allows ACTH suppression that octreotide cannot achieve. A validated, targeted treatment for a rare pituitary disorder.
- Evidence context
- Cushing's disease (ACTH-secreting pituitary adenoma), multi-receptor somatostatin pharmacology, acromegaly (LAR formulation)
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 0.6-0.9mg subcutaneous twice daily (Signifor); 40mg IM monthly (Signifor LAR)
Benefits and Evidence
- Cushing's Disease Control: Level A, includes human evidence - Phase 3 trial showed urinary free cortisol normalization in approximately 26% of patients at 6 months, with many more showing significant cortisol reduction. First medical therapy approved for Cushing's disease.
- Acromegaly Control: Level A, includes human evidence - PAOLA trial demonstrated superior GH and IGF-1 control with pasireotide LAR compared to continued octreotide LAR or lanreotide in patients inadequately controlled on first-generation somatostatin analogs.
- Hyperglycemia: Level A, includes human evidence - Hyperglycemia is the most significant adverse effect, occurring in approximately 70% of patients. Related to suppression of insulin and incretin secretion via SSTR5. Many patients require anti-diabetic therapy.
Side Effects and Warnings
- Hyperglycemia (most significant)
- Diarrhea
- Nausea
- Cholelithiasis
- Headache
- Abdominal pain
- Fatigue
- Hyperglycemia/diabetes - monitor blood glucose before and during treatment; may require anti-diabetic medication
Research Dosage References
- <strong>Subcutaneous injection</strong> - 0.3-0.9 mg - Twice daily - For Cushing's disease. Start at 0.6 mg twice daily, titrate based on urinary free cortisol response. Available as immediate-release formulation.
- <strong>Intramuscular injection</strong> - 40-60 mg - Every 28 days - Signifor LAR for acromegaly. Start at 40 mg monthly. May increase to 60 mg if inadequate response after 3 months.
Mechanism of Action
Pasireotide exerts therapeutic effects through broad somatostatin receptor activation: 1. SSTR5-predominant binding: High affinity for SSTR5, which is the predominant somatostatin receptor subtype on corticotroph adenomas, directly inhibiting ACTH secretion. 2. Multi-receptor somatostatin mimicry: Activates SSTR1, 2, 3, and 5, providing broader suppression of hormonal hypersecretion than octreotide or lanreotide. 3. ACTH suppression: Reduces adrenocorticotropic hormone (ACTH) secretion from pituitary corticotroph tumors, leading to decreased cortisol production. 4. GH/IGF-1 suppression: Inhibits growth hormone secretion in acromegaly through SSTR2 and SSTR5 activation on somatotroph adenomas.
Legal Status
FDA-approved for Cushing's disease (2012, SC formulation) and acromegaly (2014, LAR formulation). Available by prescription only. Marketed as Signifor by Recordati Rare Diseases (formerly Novartis).
Primary Sources
- Pasireotide treatment significantly reduces urinary free cortisol in Cushing's disease. J Clin Endocrinol Metab, 2012.
- Pasireotide LAR versus octreotide LAR or lanreotide in acromegaly (PAOLA). J Clin Endocrinol Metab, 2014.
- Management of pasireotide-associated hyperglycemia in Cushing's disease and acromegaly. Pituitary, 2016.
Quick Answers
Where is the strongest evidence for Pasireotide?
Pasireotide (Signifor) is FDA-approved for Cushing's disease in patients who fail surgery or are not surgical candidates, with Phase 3 data demonstrating meaningful UFC normalization. Its multi-receptor somatostatin analog profile (SST1/2/3/5) differentiates it from octreotide and allows ACTH suppression that octreotide cannot achieve. A validated, targeted treatment for a rare pituitary disorder. Evidence context: Cushing's disease (ACTH-secreting pituitary adenoma), multi-receptor somatostatin pharmacology, acromegaly (LAR formulation).
What are the main side effects of Pasireotide?
Pasireotide side effects and warning signals include Hyperglycemia (most significant), Diarrhea, Nausea, Cholelithiasis, and Headache.
What evidence level is Pasireotide?
Pasireotide is rated Level A; the listed research status is FDA Approved.